Taysha Gene Therapies(US:TSHA)2025-05-15 12:09Financial Performance - Net loss for Q1 2025 was $21.5 million, or $0.08 per share, compared to a net loss of $24.1 million, or $0.10 per share, in Q1 2024[8]. - Total operating expenses for Q1 2025 were $23.7 million, down from $27.7 million in Q1 2024, a decrease of 14.5%[17]. - General and administrative expenses increased to $8.2 million in Q1 2025, up from $7.1 million in Q1 2024, representing a 15.5% increase[7]. - Research and development expenses for Q1 2025 were $15.6 million, a decrease of 24.6% from $20.7 million in Q1 2024[6]. - As of March 31, 2025, cash and cash equivalents totaled $116.6 million, expected to support operations into Q4 2026[8]. Clinical Development - The FDA provided written alignment on key elements of the pivotal Part B trial design for TSHA-102, potentially expediting study initiation[1]. - High and low doses of TSHA-102 were well tolerated with no treatment-related serious adverse events in 10 patients across two REVEAL trials[9]. - The company anticipates providing a comprehensive regulatory update and clinical data from the REVEAL trials in Q2 2025[4]. - The company expects to submit the IND amendment for the pivotal Part B trial in Q2 2025[4]. - Taysha will host three oral presentations related to TSHA-102 at the 2025 IRSF Rett Syndrome Scientific Meeting in June 2025[9].